Logo image of TPST

TEMPEST THERAPEUTICS INC (TPST) Stock Fundamental Analysis

NASDAQ:TPST - Nasdaq - US87978U1088 - Common Stock - Currency: USD

0.8793  +0 (+0.33%)

After market: 0.87 -0.01 (-1.06%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TPST. TPST was compared to 572 industry peers in the Biotechnology industry. TPST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TPST is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TPST has reported negative net income.
TPST had a negative operating cash flow in the past year.
In the past 5 years TPST always reported negative net income.
In the past 5 years TPST always reported negative operating cash flow.
TPST Yearly Net Income VS EBIT VS OCF VS FCFTPST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

TPST has a Return On Assets of -104.97%. This is in the lower half of the industry: TPST underperforms 76.99% of its industry peers.
The Return On Equity of TPST (-310.01%) is worse than 75.93% of its industry peers.
Industry RankSector Rank
ROA -104.97%
ROE -310.01%
ROIC N/A
ROA(3y)-57.76%
ROA(5y)-63.32%
ROE(3y)-128.62%
ROE(5y)-114.41%
ROIC(3y)N/A
ROIC(5y)N/A
TPST Yearly ROA, ROE, ROICTPST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TPST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TPST Yearly Profit, Operating, Gross MarginsTPST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for TPST has been increased compared to 1 year ago.
Compared to 5 years ago, TPST has more shares outstanding
The debt/assets ratio for TPST has been reduced compared to a year ago.
TPST Yearly Shares OutstandingTPST Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
TPST Yearly Total Debt VS Total AssetsTPST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -10.11, we must say that TPST is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.11, TPST is doing worse than 74.69% of the companies in the same industry.
There is no outstanding debt for TPST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.11
ROIC/WACCN/A
WACCN/A
TPST Yearly LT Debt VS Equity VS FCFTPST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.69 indicates that TPST should not have too much problems paying its short term obligations.
TPST has a worse Current ratio (1.69) than 80.53% of its industry peers.
TPST has a Quick Ratio of 1.69. This is a normal value and indicates that TPST is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.69, TPST is doing worse than 79.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.69
Quick Ratio 1.69
TPST Yearly Current Assets VS Current LiabilitesTPST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

TPST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.64%, which is quite impressive.
EPS 1Y (TTM)28.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TPST is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.30% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.6%
EPS Next 2Y20.68%
EPS Next 3Y9.95%
EPS Next 5Y8.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TPST Yearly Revenue VS EstimatesTPST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
TPST Yearly EPS VS EstimatesTPST Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TPST. In the last year negative earnings were reported.
Also next year TPST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TPST Price Earnings VS Forward Price EarningsTPST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TPST Per share dataTPST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.68%
EPS Next 3Y9.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TPST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEMPEST THERAPEUTICS INC

NASDAQ:TPST (2/10/2025, 8:26:34 PM)

After market: 0.87 -0.01 (-1.06%)

0.8793

+0 (+0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners22.43%
Inst Owner Change-18.49%
Ins Owners0.24%
Ins Owner Change-96.65%
Market Cap38.37M
Analysts85.45
Price Target18.36 (1988.02%)
Short Float %7.18%
Short Ratio2.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.61%
Min EPS beat(2)-11.04%
Max EPS beat(2)-2.17%
EPS beat(4)2
Avg EPS beat(4)-1.02%
Min EPS beat(4)-11.04%
Max EPS beat(4)5.68%
EPS beat(8)5
Avg EPS beat(8)5.76%
EPS beat(12)8
Avg EPS beat(12)7.41%
EPS beat(16)8
Avg EPS beat(16)-44.62%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.23%
EPS NQ rev (1m)6.67%
EPS NQ rev (3m)29.41%
EPS NY rev (1m)3.44%
EPS NY rev (3m)10.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.35
P/tB 3.35
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)-1.06
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -104.97%
ROE -310.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.76%
ROA(5y)-63.32%
ROE(3y)-128.62%
ROE(5y)-114.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 104.99%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.69
Quick Ratio 1.69
Altman-Z -10.11
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)56.65%
Cap/Depr(5y)117.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.58%
EPS Next Y29.6%
EPS Next 2Y20.68%
EPS Next 3Y9.95%
EPS Next 5Y8.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.35%
EBIT Next 3Y-23.33%
EBIT Next 5Y-21.71%
FCF growth 1Y10.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.82%
OCF growth 3YN/A
OCF growth 5YN/A